The soul of the "medical headliner" is coming again! Heart stents bid farewell to the million-dollar era

(2020/09/16) Looking back at the 2010 global TOP15 biotechnology start-up decade changes more than half has been acquired; dive in a group of more than 400 pharmaceutical representatives I heard so many changes for the first time; AstraZeneta's new crown vaccine restarts the UK trial global vaccine research and development competition white heat ... Looking back at the 2010 global TOP15 biotech start-up's decade-long transformation, FierceBiotech looks back at the fortunes of Fierce 15 in 2010 to see how these companies have changed over the past decade and whether their innovative ideas have stood the test of time.
eight of the 15 companies in 2010 have been acquired or acquired, and it is worth noting that half of them involve BMS/New Base, while six are still operating independently and only one is closed.
's a pretty good result, especially since six out of 15 companies have not only stood the test of time, but have also successfully pushed a drug candidate to market through research and development.
headline bacteria: life is long.
"Eight o'clock health" in more than 400 people of medical representatives diving I first heard so many changes in the country a total of more than 3 million drug generation, industry estimates that this number will be reduced to 70,800,000 in the next few years.
layoffs, pay cuts, job-hopping, transformation ... this group is going through a lot of change.
some of them wandered through the gray areas, but also the dignity and value they felt from the profession, " the patient healed happy, and we are happy."
" headline bacteria: collection winning the bid is unemployment.
15 new inhaler drugs debuted the first inhaled antibiotics will be born! Recently, the 7th over-evaluation inhaler was born, for Mrs. Shenzhen Pharmaceuticals (Health Yuan Subsidiary) isopropyl tobly bromide inhalation solution.
meters of intranet data show that there are currently 93 inhalants (in the name of the drug plus the name of the declared enterprise) in the new classification of production, 9 have been approved for production and as reviewed; Zhengda Tianqing, four Trump Reit, Changfeng Pharmaceuticals, respectively, have 3, 3, 2 varieties of exclusive production;
: The country's first inhaled antibiotics such as arrows in the string.
health world soul cut price is coming again! Heart stent farewell era September 14, the State Medical Security Administration held in Tianjin, the national organization of high-value medical supplies centralized procurement and use of work start-up, crown stent was identified as the first batch of belt procurement varieties, centralized procurement of selected products prices and use is expected to be implemented in January 2021.
: Multiple stand products will be selected.
(Xinhua) -- AstraZeneca's new crown vaccine has restarted a UK trial of the global vaccine research and development competition white heating up Six days after AstraZeneca's new crown vaccine in partnership with Oxford University was shockingly abruptly interrupted at 14:20 bST on September 12, AstraZeneca announced on its website that clinical trials of the new crown vaccine AZD1222 have resumed in the UK after the UK Medicines and Healthcare Products Regulatory Agency (MHRA) safely confirmed that clinical trials of the new crown vaccine AZD1222 have resumed in the UK.
, however, clinical trials in other countries have not yet resumed and AstraZeneta will continue to work with health authorities around the world to recover in due course under guidance.
: The development of the new crown vaccine has driven the development of science and technology.
as an important part of the pharmaceutical industry chain when the "Pharmaceutical Rubik's Cube" CRO/CDMO breakout is carried out, CRO/CDMO company has been highly sought after by capital in recent years because of its high-quality track.
Pharmaceuticals Mingkangde, Kanglong Cheng, Tag Pharma has become the realization of A-shares, Hong Kong shares listed in the two star "A-H" shares of enterprises, the market value of the three companies total more than 400 billion yuan.
headlines: CRO/CDMO industry breakout underway.